At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LIMN Liminatus Pharma LLC
Trading 05-15 10:22:52 EDT
0.1889
+0.0049
+2.66%
High0.1890Low0.1800Vol110.77K
Open0.1800D1 Closing0.1840Amplitude4.89%
Mkt Cap8.48MTradable Cap1.80MTotal Shares44.88M
T/O20.41KT/O Rate1.16%Tradable Shares9.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Liminatus Pharma FY25 net loss widens to $10.2 million; operating loss narrows to $3 million
Reuters  ·  04-01
Liminatus Pharma FY25 net loss widens to $10.2 million; operating loss narrows to $3 million
Liminatus Pharma plans Phase 1 trial of CD47 antibody IBA101 in lung cancer
Reuters  ·  03-17
Liminatus Pharma plans Phase 1 trial of CD47 antibody IBA101 in lung cancer
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of Iba101, a Next-Generation Cd47 Blocking Antibody
THOMSON REUTERS  ·  03-17
Liminatus Pharma Announces Planned Phase 1 Clinical Trial of Iba101, a Next-Generation Cd47 Blocking Antibody
Liminatus Pharma Cuts Shareholder Meeting Quorum to One-Third
Reuters  ·  03-05
Liminatus Pharma Cuts Shareholder Meeting Quorum to One-Third
Liminatus Pharma prices 13.8M shares at 29c in public offering
TIPRANKS  ·  02-17
Liminatus Pharma prices 13.8M shares at 29c in public offering
Liminatus Pharma Announces $4 Million Public Offering With Warrants
Reuters  ·  02-17
Liminatus Pharma Announces $4 Million Public Offering With Warrants
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
THOMSON REUTERS  ·  02-17
Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering
Liminatus Pharma Inc - Offering Price Set at $0.29 per Share
THOMSON REUTERS  ·  02-17
Liminatus Pharma Inc - Offering Price Set at $0.29 per Share
Iris Acquisition Corp. II Files Initial Statement of Beneficial Ownership; Manish C. Shah Listed as Director
Reuters  ·  02-12
Iris Acquisition Corp. II Files Initial Statement of Beneficial Ownership; Manish C. Shah Listed as Director
Iris Acquisition Corp. II Announces Publication of Unqualified Independent Audit Report
Reuters  ·  02-11
Iris Acquisition Corp. II Announces Publication of Unqualified Independent Audit Report
NASD Most Active Issues
Dow Jones  ·  02-10
NASD Most Active Issues
BRIEF-Liminatus Pharma Enters Settlement Agreement With Clear Street LLC
Reuters  ·  02-10
BRIEF-Liminatus Pharma Enters Settlement Agreement With Clear Street LLC
Liminatus Pharma Inc - to Issue 4 Mln Shares of Common Stock to Holder in Exchange for Surrender and Cancellation of 805,377 Warrants
THOMSON REUTERS  ·  02-10
Liminatus Pharma Inc - to Issue 4 Mln Shares of Common Stock to Holder in Exchange for Surrender and Cancellation of 805,377 Warrants
Liminatus Pharma Inc - on Feb 6, Co Enters Settlement Agreement With Clear Street Llc - SEC Filing
THOMSON REUTERS  ·  02-10
Liminatus Pharma Inc - on Feb 6, Co Enters Settlement Agreement With Clear Street Llc - SEC Filing
Liminatus Pharma Issues 4 Million Unregistered Shares to Settle Litigation
Reuters  ·  02-10
Liminatus Pharma Issues 4 Million Unregistered Shares to Settle Litigation
NASD Most Active Issues
Dow Jones  ·  02-06
NASD Most Active Issues
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:08 PM
Reuters  ·  02-05
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:08 PM
Liminatus Pharma Faces Nasdaq Delisting Risk Over Sub-$1 Share Price
Reuters  ·  01-27
Liminatus Pharma Faces Nasdaq Delisting Risk Over Sub-$1 Share Price
Liminatus Pharma Faces Nasdaq Delisting Over Market Value Rule Breach
Reuters  ·  2025-11-26
Liminatus Pharma Faces Nasdaq Delisting Over Market Value Rule Breach
Liminatus Pharma, Inc. (Nasdaq: Limn) Signs Mou With Capital Trust Group for USD 30 Million Equity Investment via an Earn-Out Mechanism and Future Strategic Cooperation
THOMSON REUTERS  ·  2025-10-30
Liminatus Pharma, Inc. (Nasdaq: Limn) Signs Mou With Capital Trust Group for USD 30 Million Equity Investment via an Earn-Out Mechanism and Future Strategic Cooperation

Introduction

Company Name.
Liminatus Pharma LLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Iris Acquisition Corp does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was formerly known as Tribe Capital Growth Corp I and changed its name to Iris Acquisition Corp in July 2022. The company was incorporated in 2020 and is based in George Town, Cayman Islands. Iris Acquisition Corp is a subsidiary of Iris Acquisition Holdings LLC.
Issue price:
--